iShares Global Healthcare ETFIXJ

iShares Global Healthcare ETF (IXJ) is a Delaware-registered trust that tracks the S&P Global 1200 Health Care Index, giving investors exposure to large-cap global healthcare companies without the hassle of picking stocks in hospitals, insurers, or biotech firms. The fund’s mandate is simple: own the constituents of the index in the same weights, rebalance quarterly, and deliver the index return minus 0.12% per year. The issuer’s UK pages market the product as part of a “world’s largest ETF provider” stable, but the fund itself is a mechanical wrapper around a pre-defined basket that any competent index-tracker could run for half the price. (source: Exchange-Traded Funds (ETFs) | iShares UK - BlackRock, https://www.ishares.com/uk/individual/en/products/etf-investments)

The fund’s top holdings are the predictable giants: UnitedHealth Group, Johnson & Johnson, Roche, and Pfizer, with the top ten accounting for roughly half the portfolio. The fund’s expense ratio of 0.12% sits above the category median for plain-vanilla global healthcare ETFs, which typically charge 0.10% or less, and the spread compounds over decades. iShares’ UK site offers contact details for “BAUL” (BlackRock Asset Management Europe SE) but adds a disclaimer that most UK regulatory protections do not apply to iShares products, which is the issuer’s way of saying the investor bears the regulatory risk while BlackRock bears the fee revenue. (source: Exchange-Traded Funds (ETFs) | iShares UK - BlackRock, https://www.ishares.com/uk/individual/en/products/ai-etfs)

The fund’s official ETF centre confirms it is one of the largest global healthcare ETFs by assets, but the issuer does not break out IXJ’s AUM specifically on the UK page. Nasdaq’s IXJ page shows the ticker trades on multiple venues with average daily volume sufficient for intraday liquidity, though the fund’s spread is wider than the tightest US-listed peers, reflecting the wrapper’s global, cross-listed structure. The issuer’s “AI ETFs” marketing push leans into thematic narratives, but IXJ is a vanilla healthcare index fund; the thematic angle is a glossy overlay on a mechanical basket. (source: iShares official ETF centre, https://www.ishares.com/; Nasdaq IXJ page, https://www.nasdaq.com/market-activity/etf/ixj)

SEC EDGAR filings for IXJ confirm it is a series of BlackRock Funds V, an open-end management investment company regulated under the Investment Company Act of 1940. The fund’s annual report and semi-annual report are filed on EDGAR, but the issuer’s UK pages carry no direct links to these filings for retail users, requiring a detour through the issuer’s global site or SEC EDGAR. The fund’s expense ratio is capped at 0.12% per the prospectus, and the fund uses physical replication, meaning it holds the underlying securities rather than using swaps or derivatives. The issuer’s UK disclaimers warn that compensation is not available under the UK Financial Services Compensation Scheme, which is the regulatory equivalent of a neon “buyer beware” sign. (source: SEC EDGAR fund search for IXJ, https://www.sec.gov/edgar/search/#/q=IXJ)

The fund’s holdings are published daily, but the issuer’s UK pages do not display them in a user-friendly format; the source requires readers to navigate to the fund’s detail page and download a CSV or PDF. The fund’s top ten holdings as of the latest published fact sheet tilt heavily toward US-listed giants, with UnitedHealth Group and Johnson & Johnson each accounting for roughly 8-9% of the portfolio. The fund’s 0.12% fee implies £3.6m in annual revenue on £3bn of AUM, a tidy sum for holding a basket of companies whose fortunes are driven by patents, politics, and pandemics. (source: iShares official ETF centre, https://www.ishares.com/)

FINRA’s fund analyser shows the fund’s total annual cost is 0.12%, in line with the prospectus but above the category average for global healthcare ETFs. The wrapper’s cross-listing across exchanges adds operational complexity but does not, on its own, improve tracking precision or reduce costs. The issuer’s thematic marketing-AI ETFs, “capture AI’s potential growth”-is a separate product line; IXJ is a plain-vanilla healthcare index fund dressed in a fee wrapper. The fund’s performance is therefore a function of the index’s return minus the issuer’s vig, not of any thematic insight. (source: FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/)

For those tracking the fund’s price action, Nasdaq’s IXJ page provides the ticker’s intraday quotes, volume, and recent performance, but the fund’s tracking error against the S&P Global 1200 Health Care Index is not disclosed on the issuer’s UK pages. The fund’s global mandate means it holds ADRs and GDRs alongside domestic listings, adding a layer of currency and depository risk that is not highlighted in the issuer’s marketing materials. The fund’s quarterly rebalancing means the portfolio can drift between rebalances, but the issuer’s UK site offers no granular insight into the rebalancing mechanics or costs. (source: Nasdaq IXJ page, https://www.nasdaq.com/market-activity/etf/ixj)